A Phase 1/2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma ( s21-00991)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Adenocarcinoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have pathologically confirmed pancreatic adenocarcinoma. 2) Received 4-6 months of induction chemotherapy with either fluorouracil, irinotecan, leucovorin and oxaliplatin (FOLFIRINOX) or gemcitabine/Abraxane, as per standard of care. 3) Patients must have locally advanced pancreatic cancer according to National Comprehensive Cancer Network (NCCN) Guidelines (Version 1.2020) on CT scan performed within 21 days of registration.

You may not be eligible for this study if the following are true:

  • 1) Patients who have completed induction chemotherapy less than 2 weeks or more than 8 weeks prior to study enrollment. 2) Patients who have not recovered from adverse events due to prior anti-cancer therapy. 3) Patients with mild reactions may be enrolled, but must receive premedications for contrast allergy prior to imaging.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.